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ABSTRACT
Objective: Despite the suggested role of vitamin D in
the prevention of diabetes and cardiovascular disease
or its risk factors, the evidence is not consistent and
there is a paucity of randomized controlled trials in this
field. We aimed to investigate the effect of 16-week
daily vitamin D3 supplementation on glycated
hemoglobin (HbA1c), fructosamine, body mass index
(BMI), and serum lipids.
Design: Double-blind, randomized, placebo-controlled
trial.
Setting: Immigrant community centers in Oslo,
Norway.
Participants: 251 healthy adults aged 18–50 years
with a non-Western immigrant background. All
participants performed the baseline test and 215
(86%) returned to the follow-up test.
Intervention: 16 weeks of daily oral supplementation
with either 10 μg vitamin D3, 25 μg vitamin D3, or
placebo.
Main outcome measures: Difference in absolute
change during the 16-week intervention between the
intervention groups combined (10 or 25 μg of vitamin
D3/day) and placebo, in HbA1c, fructosamine, serum
lipids (total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, and
triglycerides), and BMI.
Results: A total of 215 (86%) participants completed
the study. Serum 25-hydroxyvitamin D increased from
29 nmol/L at baseline to 49 nmol/L after intervention,
with little change in the placebo group. However, there
was no difference in change of HbA1c between those
receiving vitamin D3 compared with placebo (mean
difference: 0.01% (95% CI −0.04 to 0.06, p=0.7)).
Neither did the vitamin D3 supplementation have any
effect on the other end points: fructosamine, serum
lipids, and BMI.
Conclusions: 16-week vitamin D3 supplementation to
healthy immigrants from South Asia, the Middle East,
or Africa and now living in Norway with low vitamin D
status did not improve HbA1c, fructosamine, lipid
profiles, or BMI. An updated meta-analysis of similar
published trials showed that our results were generally
consistent with those of other studies.
Trial registration number: NCT01263288.
INTRODUCTION
Vitamin D deﬁciency is widespread among
immigrants from non-Western countries in
Europe and elsewhere.1–4 Classical outcomes
of severe vitamin D deﬁciency are rickets in
children and osteomalacia in adults. Low
vitamin D status is also a risk factor for low
bone density and osteoporotic fractures.
Furthermore, during the past decades, the
vitamin D receptor has been found in many
tissues and new actions of vitamin D have
been described.5
Immigrants, particularly those from South
Asia and the Middle East, are at high risk of
type 2 diabetes6–8 and have a high prevalence
of cardiovascular risk factors such as unfavor-
able serum lipids.9 10 Several epidemiological
studies have suggested increased risks of dia-
betes or impaired glucose metabolism and
cardiovascular diseases among persons with
low vitamin D status.11–14
Key messages
▪ Immigrants are at risk both for viatmin D
deficiency, overwieght and diabetes type-2.
▪ Effective and specific preventive means for
vitamin D deficiency, overweight and risk of dia-
betes in immigrant population should be
explored.
▪ More studies are needed to study the long-term
health consequences of the low vitamin D status
of immigrants.
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Despite the suggested role of vitamin D in the preven-
tion of diabetes and cardiovascular disease, the evidence
is not consistent and there is a paucity of randomized
controlled trials (RCTs) assessing the effect of vitamin D
supplementation on these outcomes. In particular, few
studies have been carried out on immigrants living in
developed countries, who are at increased risk of both
hypovitaminosis D and diabetes.6 To study whether
vitamin D supplementation has an effect on glucose
metabolism, serum lipids and body mass index (BMI) in
healthy adults with an immigrant background in Norway,
we have carried out a randomized, double-blinded, con-
trolled trial.
Results from the primary end point have previously
been reported.15 We present results from predeﬁned
additional end points. The aim was to test whether
16 weeks of daily vitamin D3 supplementation (10 or
25 µg/day vs placebo) would reduce glycated hemoglo-
bin (HbA1c), fructosamine,and BMI and improve serum
lipids.
RESEARCH DESIGN AND METHODS
Study design and participants
The study was conducted between January and June 2011
and further details of the study method have been
described elsewhere.15 Participants were healthy men
and women, aged 18–50 years, who were born or had
parents born in the Middle East, Africa, and South Asia.
They were recruited through 11 different community
centers in Oslo and surrounding areas (at latitude 60°N).
They were excluded if they regularly used vitamin
D-containing supplements, were receiving treatment for
vitamin D deﬁciency, were pregnant or breastfeeding,
used medication for hypoglycemia or hyperlipidemia,
malabsorption, used medication interfering with the
vitamin D metabolism (such as thiazides, antiepileptic
drugs, prednisolone, or hormone replacement therapy),
had kidney disease, cancer, tuberculosis, sarcoidosis,
osteoporosis, or a recent fracture, or used strong painkil-
lers prescribed by a physician such as Paralgin forte and
Aporex. The same data collection team visited all the
centers and performed the baseline and follow-up data
collection. Interpreters were used when necessary, but
the majority of the study participants were able to com-
municate in the Norwegian language.
RANDOMIZATION AND INTERVENTION
Those who fulﬁlled the eligibility criteria were randomly
assigned to one of three equally sized intervention
groups receiving one tablet per day containing 25 μg
vitamin D3, 10 μg vitamin D3, or placebo. The tablets
were similar in color, size, and packing. Each study par-
ticipant was given a box of 120 tablets (a 16-week use
corresponds to 112 tablets) at baseline with a self-
administered compliance form. The tablets were manu-
factured by Bioplus Life Sciences Pvt Ltd, DMA
(Bangalore, India), certiﬁed for Good Manufacturing
Practice, and the ingredients met the requirements of
British Pharmacopé. If the study participants had forgot-
ten to take one tablet a day, they were asked to take two
tablets the following day. The participants were followed
up with a short text message twice a week to remind
them to take the tablets. They were advised to maintain
their usual dietary pattern during the 16-week trial
period and contact the study staff by telephone if they
had any inquiries.
MAIN OUTCOME VARIABLES
The study outcomes were difference in absolute change
during the 16-week intervention between the interven-
tion groups combined (10 or 25 μg of vitamin D3/day)
and placebo, in HbA1c, fructosamine, serum lipids
(total cholesterol, low-density lipoprotein (LDL) choles-
terol, high-density lipoprotein (HDL) cholesterol, and
triglycerides), and BMI. HbA1c is correlated with the
average glucose level over the preceding 2–3 months,16
and it can be measured in non-fasting blood samples.
Fructosamine reﬂects the average blood glucose level
over the preceding 2–3 weeks, and the assay is not inﬂu-
enced by hemoglobinopathies or iron deﬁciency anemia
that may inﬂuence HbA1c measurements.17
BLOOD SAMPLING AND LABORATORY ASSAYS
Non-fasting venous blood was drawn at baseline and at
the follow-up after 16 weeks. Blood for serum was col-
lected in serum-separator gel tubes and centrifuged
after 30 min to 2 h, and blood for plasma was collected
in EDTA tubes and centrifuged within 30 min at room
temperature at the study site. Serum and plasma were
separated and frozen in several aliquots at −20°C the
same day and within 1–2 weeks frozen at −80°C until
they were analyzed. After the completion of the study,
all serum samples from baseline and follow-up were ana-
lyzed in one batch at the Fürst Medical Laboratory
(http://www.furst.no), which is accredited by the
International Organization for Standardization and is
part of the vitamin D External Quality Assessment
Scheme (DEQAS).
Serum 25-hydroxyvitamin D (s-25(OH)D) was mea-
sured using high-pressure liquid chromatography
tandem mass spectrometry, with Waters Acquity UPLC
and Waters triple quadrupole mass spectrometer instru-
ments. Both 25(OH)D2 and 25(OH)D3 levels were mea-
sured and the sum of the two was used for analysis
(termed 25(OH)D, even though 25(OH)D2 was negli-
gible). The within-batch coefﬁcient of variation for s-25
(OH)D3 was 4.8% within high concentrations and 7.2%
within low concentrations.
HbA1c was analyzed on a cation exchange column
chromatograph using an automated high-pressure liquid
chromatography instrument (HLC-723 G7, Tosoh
Corporation, Tokyo, Japan). The reference upper
normal for HbA1c is <6.1%. The total coefﬁcient of vari-
ation was 2% at HbA1c levels around 6.1%.
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Fructosamine was measured using a colorimetric
enzymatic method (ADVIA 2400 Siemens). The interas-
say coefﬁcient of variation (CV) was 2.3% and reference
upper normal was 285 µmol/L.
Total cholesterol, LDL-cholesterol, HDL-cholesterol,
and triglycerides were measured using an enzymatic
method (ADVIA 2400 Siemens). The interassay coefﬁ-
cients of variation were 1.3% (total cholesterol), 1.6%
(LDL-cholesterol), 1.8% (HDL-cholesterol), and 3.8%
(triglycerides).
Body weight was measured with a Bosogramm 3000
Scale (loading capacity 150 kg) to the nearest 100 g with
participants in indoor clothing without shoes. Height
was measured to the nearest centimeter with a rigid
meter standard. The same devices were used both at
baseline and at follow-up. The participants completed
an interviewer-administered questionnaire at baseline
and follow-up. Information about age, ethnicity, educa-
tion, and duration of residence in Norway was collected
at baseline.
RANDOM ALLOCATION
We chose a computer-generated block randomization to
ensure a good balance of the number in each group
during the trial and randomly varied the block size
between 3 and 6.
BLINDING
Group allocation was unknown to participants, research
staff, investigators, and data collectors. Data analyses
were also blinded. The tablet boxes were numbered
according to the randomization list by an external phar-
macy (the Hospital Pharmacy at Oslo University
Hospital). The group allocation list was stored at this
pharmacy with a copy in a sealed envelope. Each partici-
pant was consecutively numbered and received a pre-
packaged tablet box with the corresponding number.
The analyses of the primary outcome measures and the
evaluation of the physical performance tests were per-
formed before the randomization list was opened. At
the end, the results of s-25(OH)D and plasma parathy-
roid hormone (PTH) analyses at follow-up were
unmasked.
REGISTRATION
The study was authorized as a clinical trial by the
Norwegian Medicine Agency. It has been registered at
EudraCT (2010-021114-36). The clinical trial was con-
ducted according to the principles of the Declaration of
Helsinki and in accordance with national laws
(ClinicalTrials.gov identiﬁer NCT01263288).
STATISTICAL ANALYSES
The sample size was planned for an effect of the inter-
vention on muscle strength and power. This was the
main end point of the trial, and these results are
presented elsewhere.15 This suggested that we should
include 210 participants, and under the assumption of
expected dropout rates of 15–20% we aimed to recruit
at least 250 participants. We also calculated that this
sample size would provide 80% power to detect a differ-
ence of 0.5 (% points) in HbA1c between the interven-
tion and control groups, a difference we considered
clinically relevant.18
Statistical analysis of the data was performed using the
IBM SPSS statistical software (V.19.0; SPSS Inc, Chicago,
Illinois, USA). For each of the outcome variables, we cal-
culated the difference in change from baseline to
follow-up between the combined intervention groups
(10 or 25 μg/day) and the placebo group. This was ana-
lyzed using linear regression analysis, where the effect
on each outcome variable was adjusted for the respective
baseline concentration. Similar analyses were also per-
formed to compare 25 μg/day to placebo and 10 μg/day
to placebo. p Values <0.05 were considered statistically
signiﬁcant.
Subgroup analyses by baseline values of end point
measures, gender, and intervention dose were also
performed.
All participants provided written consent. The partici-
pants were instructed that they would receive a notiﬁca-
tion by letter, if the analysis of their blood sample later
showed deviant values with a recommendation to
contact their regular general practitioners.
Role of the funding source
Nycomed, which supplied study tablets and other spon-
sors, had no role in the study design, data collection, data
analysis, data interpretation, or writing of the report.
RESULTS
Participants
We screened 301 persons for inclusion in the study, of
whom 251 met the inclusion criteria and agreed to par-
ticipate. They were randomly assigned to one of the three
intervention groups. After 16 weeks, 215 (86%) study par-
ticipants returned to the follow-up visit, including one
who declined to take the blood sample (ﬁgure 1).
Baseline characteristics
No substantial between-group differences in baseline
values were noted (table 1). The mean baseline s-25
(OH)D concentration for the whole study population
was 28.9 (SD 17.6) nmol/L and 90% had s-25(OH)D
<50 nmol/L while 53% had s-25(OH)D <25 nmol/L.
Around 38% had HbA1c levels equal to or above 5.7%.
The baseline correlation between HbA1c and serum
fructosamine was 0.47 (p<0.001). There was no signiﬁ-
cant difference in baseline variables in the participants
who did not complete the study (n=37) compared with
those completed the study (n=214).
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Figure 1 Flow chart of recruitment, randomization, and follow-up.
Table 1 Baseline characteristics for study participants by supplementation group*
Characteristics
Vitamin D (25 µg)
N=84




Age (years) 36 (8.2) 37 (7.6) 39 (7.6)
Sex (n, %)
Male 26 (31) 24 (28) 19 (23)
Female 58 (69) 61 (72) 63 (77)
Regional origin (n, %)
South Asia 31 (37) 31 (36) 33 (40)
Middle East and North Africa 15 (18) 9 (11) 12 (15)
Sub-Saharan Africa 38 (45) 45 (53) 37 (45)
Years lived in Norway (mean, range) 13.3 (1–29) 13.2 (1–35) 13.6 (2–33)
Level of education, years (n, %)
≤10 34 (40) 36 (42) 33 (40)
11–13 30 (36) 31 (37) 34 (42)
≥14 20 (24) 18 (21) 15 (18)
S-25(OH)D (nmol/L) 26.9 (16.5) 29.8 (20.6) 30.1 (18.9)
HbA1c (%)† 5.6 (0.65) 5.6 (0.51) 5.6 (0.43)
Fructosamine (µmol/L) 251 (50.5) 248 (35.9) 245 (30.1)
Total cholesterol (mmol/L) 4.8 (0.79) 4.9 (0.82) 4.9 (0.90)
HDL-cholesterol (mmol/L) 1.4 (0.31) 1.4 (0.31) 1.4 (0.32)
LDL-cholesterol (mmol/L) 3.3 (0.85) 3.3 (0.88) 3.4 (0.86)
Triglycerides (mmol/L) 1.6 (0.91) 1.5 (1.2) 1.6 (1.13)
BMI (kg/m2) 26.9 (5.2) 27.5 (5.2) 27.8 (5.0)
*Data are mean (SD) unless specified otherwise.
†N=246. Thirty-seven participants did not come back to follow-up; 11 in placebo, 16 in the 10 µg group, and 10 in the 25 µg group. The
baseline characteristics of these were not different from those who completed the study.
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; S-25(OH)D, serum
25-hydroxyvitamin D.
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Effect of supplementation on vitamin D status
S-25(OH)D increased from a mean of approximately
29 nmol/L at baseline to 49 nmol/L after intervention,
with little change in the placebo group (table 2).
Effect of supplementation on end point measures
A 16-week supplementation with vitamin D3 (10 or 25 µg
combined compared) to placebo had no signiﬁcant
effect on HbA1c, fructosamine, total cholesterol, LDL,
HDL, and triglycerides or BMI (table 2).
Subgroup analyses
There were no signiﬁcant effects on outcome variables
in subgroups deﬁned by baseline values (ﬁgure 2).
There were also no signiﬁcant effects of 25 µg vitamin D
versus placebo on any of the end points (data not
shown).
Furthermore, there were no signiﬁcant differences
between the combined intervention groups and placebo
in any of the end points after stratiﬁcation by baseline
concentration of s-25(OH)D higher or lower than
25 nmol/L, or after stratiﬁcation by gender (data not
shown).
Table 2 Effect of vitamin D supplementation* on markers of glucose metabolism, serum lipids, and body mass index
Baseline‡ After 16 weeks‡
Change from
baseline to 16 weeks‡
Difference (95% CI)
compared to placebo† p Value
S-25(OHD) (nmol/L)
Intervention (n=143) 28.7 (18.6) 48.8 (19.6) 20.1 (21.7) 21.3 (16.7 to 26.0) <0.0001
Placebo (n=71) 29.2 (15.6) 27.5 (13.7) −1.5 (11.3)
HbA1c (%)§
Intervention (n=139) 5.65 (0.6) 5.68 (0.7) 0.03 (0.17) 0.01 (−0.04 to 0.06) 0.7
Placebo (n=70) 5.52 (0.4) 5.52 (0.5) 0.01 (0.18)
S-fructosamine (µmol/L)
Intervention (n=143) 251 (45.9) 249.5 (58.4) −1.1 (27.6) 1.7 (−5.3 to 8.7) 0.6
Placebo (n=71) 245 (30.8) 242.8 (29.9) −3.2 (16.5)
Total cholesterol (mmol/L)
Intervention (n=143) 4.9 (0.8) 4.8 (0.8) −0.1 (0.5) −0.03 (−0.17 to 0.12) 0.7
Placebo (n=71) 4.9 (0.9) 4.8 (0.8) −0.1 (0.5)
LDL-cholesterol (mmol/L)
Intervention (n=143) 3.3 (0.8) 3.2 (0.8) −0.06 (0.4) −0.01 (−0.1 to 0.1) 0.9
Placebo (n=71) 3.3 (0.8) 3.3 (0.8) −0.05 (0.5)
HDL-cholesterol (mmol/L)
Intervention (n=143) 1.4 (0.3) 1.37 (0.3) −0.01 (0.2) −0.002 (−0.05 to 0.05) 0.9
Placebo (n=71) 1.4 (0.3) 1.39 (0.3) −0.02 (0.2)
Triglycerides (mmol/L)
Intervention (n=143) 1.6 (1.1) 1.4 (0.8) −0.18 (0.9) 0.03 (−0.2 to 0.20) 0.7
Placebo (n=71) 1.5 (1.1) 1.3 (0.7) −0.16 (0.9)
BMI (kg/m2)
Intervention (n=143) 26.9 (4.9) 26.9 (5.1) −0.03 (0.6) −0.05 (−0.2 to 0.1) 0.6
Placebo (n=71) 28.1 (5.2) 28.1 (5.2) 0.02 (0.7)
*Combined 10 and 25 µg doses of vitamin D.
†Adjusted for baseline values.
‡Data are mean (SD) unless specified otherwise.
§N=209. Five participants had insufficient amount of blood for HbA1c measurements. The mean age of these was 32 years and the s-25(OH)D
was 36.4 nmol/L (16.7), three persons were in the 10 µg group while the others were in the two other groups each.
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; S-25(OH)D, serum
25-hydroxyvitamin D.
Figure 2 Subgroup analysis. Effect of vitamin D
supplementation on outcome variables in subgroups defined
by baseline levels of the respective outcome variables. Effect
estimates for each outcome variable are difference in change
from baseline to 16 weeks between the combined intervention
groups (10 or 25 µg) and the placebo group. Within each
subgroup, the effect estimate was adjusted for the baseline
level of the respective outcome variables (baseline value
entered as a continuous variable in the regression model).
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DISCUSSION
Principal findings
In this study, we found that a 16-week supplementation
with either 10 or 25 µg vitamin D3 daily to healthy immi-
grants from South Asia, the Middle East, or Africa and
now living in Norway did not signiﬁcantly affect HbA1c,
fructosamine, serum lipids, or BMI. Notably, the 95% CI
for mean difference in HbA1c (−0.04 to 0.06) excluded
−0.5%, which was our a priori deﬁned smallest differ-
ence of clinical relevance. We can therefore reasonably
exclude large effects on HbA1c of a 16-week interven-
tion with these dosages.
Strengths and weaknesses
The study was a strictly performed double-blinded, ran-
domized, placebo-controlled trial with good compliance
and relatively high retention. According to our prestudy
power calculation, our relatively large sample size should
provide good statistical power to detect even
small-to-moderate effects on HbA1c. Blood samples were
assayed in one batch. In addition to the commonly mea-
sured HbA1c, we also included fructosamine, which
refers to glycated serum proteins and reﬂects the
average blood glucose levels for the previous 2–3 weeks.
We reasoned that this would increase the chance of
detecting changes during a 16-week intervention period.
The ethnic minorities targeted in our study are known
to have a generally poor vitamin D status and relatively
high risk of type 2 diabetes and other cardiovascular risk
factors, as conﬁrmed in our study.1 6 19 20 The study also
has some limitations. It was designed primarily for mus-
cular strength outcomes, but HbA1c was an important
prespeciﬁed outcome described in the protocol. We did
not measure fasting glucose levels and insulin sensitivity,
which would have been more demanding for the partici-
pants with possibly negative effects on recruitment and
participation of the study participants. Also, the partici-
pants may not have been exposed for a sufﬁciently long
time to high levels of circulating s-25(OH)D to affect
some of our outcome variables.
Findings in relation to other studies
A recently published systematic review and meta-analysis
concluded that currently there is insufﬁcient evidence
to recommend vitamin D supplementation in order to
improve glycemia or insulin resistance in patients with
diabetes, normal fasting glucose, or impaired glucose
tolerance.21 In the systematic review, only four studies
examined HbA1c as an outcome, and all were done in
participants with diabetes or another serious chronic
disease, or the intervention was done with
1-hydroxyvitamin D, which circumvents the strictly
controlled hydroxylation of the 1-position (normally of
25(OH)D).
A few other relevant studies including healthy partici-
pants with low vitamin D status have been published
after the systematic review cited above. Studies with
similar characteristics as ours, with a duration of 3–
12 months, consistently did not show clear effects on
HbA1c (see online electronic supplementary material
for details), and generally supported our result. For
instance, Davidson et al22 examined healthy persons
from ethnic minorities in the USA (Latinos and
African-Americans) with HbA1c >5.8% and s-25(OH)D
<75 nmol/L at baseline. They showed no effect of high
doses of vitamin D supplementation (doses correspond-
ing to >200 µg/day) for 1 year on various measures of
glycemia or insulin sensitivity. HbA1c was slightly
reduced in those receiving vitamin D, but the effect size
was deemed clinically non-relevant. While we did not
restrict participants by baseline s-25(OH)D or HbA1c,
the large majority of our participants in our study had
levels <50 nmol/L and many had HbA1c >5.7%. Harris
et al23 gave a 3-month supplementation with 4000 IU
(100 µg) vitamin D3 daily in overweight
African-Americans with prediabetes but found no effect
on HbA1c or other measures of glycemia. A RCT by
Mitri et al24 examining the effect of vitamin D supple-
mentation in adults at high risk of diabetes concluded
that short-term supplementation with cholecalciferol did
not have a signiﬁcant effect on HbA1c.
In two other relatively large studies performed in the
North of Norway, capsules of 20 000 IU (500 µg) vitamin
D3 or placebo were given twice weekly for 6 months to
healthy Norwegians with s-25(OH)D levels <50 nmol/L,
but the intervention did not improve HbA1c.25 We did
not identify any other randomized studies of the effect
of vitamin D on fructosamine. The lack of effect on fruc-
tosamine is nevertheless consistent with the lack of
effect on HbA1c and on fasting glucose seen in other
studies21 since fructosamine also reﬂects aspects of
glucose metabolism.
Results from systematic reviews of RCTs of vitamin D
on lipids show a lack of effect of vitamin D on total chol-
esterol, LDL-cholesterol, and HDL-cholesterol which was
clearly consistent with our study.13 26 Also, our updated
meta-analysis of recent trials similar to ours supported
the lack of effect of vitamin D on serum total cholesterol
in healthy adults (confer electronic supplementary
material). A consistent lack of effect of vitamin D on
serum lipids was also found in a 12-month study among
Pakistani immigrants in Copenhagen, Denmark.27
A recently conducted review of RCTs on either
vitamin D plus calcium or only vitamin D, and reporting
effects on adiposity outcomes including BMI, concluded
that current evidence from RCTs did not consistently
support the contention that calcium and vitamin D
accelerated weight or fat loss in obesity.28 Also, von
Hurst et al conducted a randomized controlled study in
81 women of South Asian origin living in New Zealand
and aged 23–68 years to 6 months of supplementation
with 100 µg/day of vitamin D or placebo and stated that
there was no signiﬁcant effect on BMI. In accordance
with other RCTs, we did not ﬁnd any effect of vitamin D
supplementation on BMI.29 30 Our updated
meta-analysis on BMI clearly showed that there was no
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indication on an effect of vitamin D on BMI in healthy
adults (see online electronic supplementary material).
In our study, both doses of vitamin D supplementation
were sufﬁcient to raise s-25(OH)D concentration signiﬁ-
cantly compared with the placebo group, but
≥50 nmol/L was not reached in 43% (25 μg supplemen-
tation group) and 62% (10 μg supplementation group).
The existing literature on the effect of vitamin D on
the end points included in our study did not identify
any effects even when higher doses (even above 100 µg/
day) and longer duration (up to 12 months) of treat-
ment with vitamin D were used. Thus, we believe that
the lack of effect in our study would not change with
another regime of vitamin D treatment.
In conclusion, in healthy adults with an immigrant
background low in vitamin D, supplementation with
vitamin D3 during 16 weeks did not improve HbA1c,
fructosamine, lipid proﬁles, and BMI. Our literature
review and updated meta-analysis showed that the lack
of effect of vitamin D on these end points in healthy
adults was consistent and corroborated by other similar
studies.
Future research
Over 1/3 of the study participants had prediabetes
HbA1c levels and are at risk of development of diabetes;
therefore, exploring effective preventive means for
vitamin D deﬁciency, diabetes, and cardiovascular
disease is urgently needed. Also, more work is needed to
study the long-term health consequences of the low
vitamin D status of immigrants.
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